Baricitinib

Sort by

1,3-bis(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,...

  • CAT Number DCTI-C-347
  • CAS Number NA
  • Molecular Formula C17H31BN2O4
  • Molecular Weight 338.26

1,5-bis(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,...

  • CAT Number DCTI-C-346
  • CAS Number NA
  • Molecular Formula C17H31BN2O4
  • Molecular Weight 338.26

2-(1-(ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)e...

  • CAT NUMBER DCTI-C-1823
  • CAS NUMBER 1187594-13-3
  • MOLECULAR FORMULA C22H31N7O3SSi
  • MOLECULAR WEIGHT 501.68

2-(1-(ethylsulfonyl)-3-(4-(7-(hydroxymethyl)-7H-py...

  • CAT Number DCTI-C-295
  • CAS Number 1187595-89-6
  • Molecular Formula C17H19N7O3S
  • Molecular Weight 401.45

4-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine

  • CAT Number DCTI-C-1824
  • CAS Number 952518-97-7
  • Molecular Formula C9H7N5
  • Molecular Weight 185.19

Baricitinib Acid Impurity

  • CAT Number DCTI-C-294
  • CAS Number 2271228-52-3
  • Molecular Formula C16H18N6O4S
  • Molecular Weight 390.42

Baricitinib Amide Impurity

  • CAT Number DCTI-C-1154
  • CAS Number 2271228-51-2
  • Molecular Formula C16H19N7O3S
  • Molecular Weight 389.43

Baricitinib D5

  • CAT NUMBER DCTI-A-340
  • CAS NUMBER 1564241-79-7
  • MOLECULAR FORMULA C16H12D5N7O2S
  • MOLECULAR WEIGHT 376.45

N-((3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyra...

  • CAT NUMBER DCTI-C-1822
  • CAS NUMBER NA
  • MOLECULAR FORMULA C16H18N6O4S
  • MOLECULAR WEIGHT 390.42

General Information

Baricitinib Impurities and Baricitinib 

Daicel Pharma synthesizes high-quality Baricitinib impurities, including 2-(1-(ethylsulfonyl)-3-(4-(7-(hydroxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile, Baricitinib Acid Impurity, Baricitinib Amide Impurity, N-((3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-5-oxotetrahydrofuran-3-yl)methyl) ethanesulfonamide, 2-(1-(ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl) acetonitrile, and so on. These impurities are essential for evaluating the quality, stability, and safety of Baricitinib, an active pharmaceutical ingredient. Additionally, Daicel Pharma offers a customized synthesis of Baricitinib impurities for global delivery to meet the specific needs of our customers.

Baricitinib [CAS: 1187594-09-7] is a small-molecule Janus kinase (JAK) inhibitor. It treats moderate-to-severe rheumatoid arthritis, alopecia areata, and severe COVID-19 in hospitalized patients who require oxygen supplementation. Baricitinib reduces inflammation, modulates the immune system, and has antineoplastic properties.

Baricitinib: Use and Commercial Availability  

Baricitinib is an antirheumatic drug approved by the US FDA for use in adults with moderately to severely active rheumatoid arthritis who have not responded adequately to other disease-modifying antirheumatic drugs, such as TNF antagonist therapies. Baricitinib is available under the trade name Olumiant.

Baricitinib Structure and Mechanism of Action Baricitinib Structure and Mechanism of Action

The chemical name of Baricitinib is 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidine acetonitrile. Its chemical formula is C16H17N7O2S, and its molecular weight is approximately 371.4 g/mol.

Baricitinib inhibits Janus kinases, enzymes that transmit signals from cytokine or growth factor-receptor interactions on the cellular membranes.

Baricitinib Impurities and Synthesis

During the manufacturing1 of Baricitinib, impurities may form in the drug substance, which can affect its safety and efficacy. Some common Baricitinib impurities include related compounds, degradants, and residual solvents. Therefore, it is essential to control them and ensure the purity of the drug substance.

Daicel Pharma provides a Certificate of Analysis (CoA) for Baricitinib impurity standards, including 2-(1-(ethylsulfonyl)-3-(4-(7-(hydroxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile, Baricitinib Acid Impurity, Baricitinib Amide Impurity, N-((3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-5-oxotetrahydrofuran-3-yl)methyl) ethanesulfonamide, 2-(1-(ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl) acetonitrile, and so on. The CoA is generated from a cGMP-compliant analytical facility and includes comprehensive characterization data such as 1H NMR, 13C NMR, IR, MASS, and HPLC purity. We can also give additional characterization data like 13C-DEPT and CHN on request. Daicel Pharma is capable of creating unknown Baricitinib impurities or degradation products. Each delivery has a complete characterization report.

References
FAQ's

Frequently Asked Questions

Impurities in Baricitinib are controlled during manufacturing by implementing good manufacturing practices (GMP), such as using high-quality raw materials and employing appropriate purification techniques.

Yes, impurities in Baricitinib can affect the stability of the drug product, leading to degradation and decreased efficacy.

Yes, specific methods to control impurities in Baricitinib depend on the type of impurity and its source. For example, controlling process-related impurities involves optimizing synthetic processes and using appropriate purification techniques.

Baricitinib impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).

Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.

Back to Top
Product has been added to your cart